Wealth Alliance Buys 750 Shares of Zoetis Inc. (NYSE:ZTS)

Wealth Alliance increased its stake in shares of Zoetis Inc. (NYSE:ZTS) by 6.2% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 12,759 shares of the company’s stock after buying an additional 750 shares during the period. Wealth Alliance’s holdings in Zoetis were worth $2,212,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of ZTS. Price T Rowe Associates Inc. MD boosted its holdings in shares of Zoetis by 31.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 13,716,681 shares of the company’s stock worth $2,707,262,000 after buying an additional 3,244,074 shares during the period. Sarasin & Partners LLP raised its stake in Zoetis by 546.3% in the 2nd quarter. Sarasin & Partners LLP now owns 2,253,590 shares of the company’s stock worth $390,682,000 after purchasing an additional 1,904,899 shares in the last quarter. Swedbank AB acquired a new stake in Zoetis in the 1st quarter worth about $210,815,000. Public Employees Retirement Association of Colorado acquired a new stake in Zoetis in the 4th quarter worth about $242,757,000. Finally, CIBC Private Wealth Group LLC raised its stake in Zoetis by 122.6% in the 4th quarter. CIBC Private Wealth Group LLC now owns 1,448,665 shares of the company’s stock worth $285,923,000 after purchasing an additional 797,884 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have weighed in on ZTS. BTIG Research lifted their price objective on shares of Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Argus upgraded shares of Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. Piper Sandler lifted their price objective on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 14th. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $200.00 price objective on shares of Zoetis in a research note on Tuesday, August 27th. Nine equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Zoetis has a consensus rating of “Buy” and a consensus target price of $217.11.

Zoetis Price Performance

Shares of NYSE:ZTS opened at $195.74 on Wednesday. The firm has a 50 day moving average of $183.65 and a 200-day moving average of $174.15. The stock has a market capitalization of $88.68 billion, a PE ratio of 37.71, a PEG ratio of 2.98 and a beta of 0.88. The company has a current ratio of 3.45, a quick ratio of 2.09 and a debt-to-equity ratio of 1.32. Zoetis Inc. has a 12 month low of $144.80 and a 12 month high of $201.92.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Tuesday, August 6th. The company reported $1.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.49 by $0.07. The business had revenue of $2.36 billion during the quarter, compared to analysts’ expectations of $2.31 billion. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. The firm’s quarterly revenue was up 8.3% compared to the same quarter last year. During the same period in the prior year, the company earned $1.41 EPS. On average, equities research analysts predict that Zoetis Inc. will post 5.84 EPS for the current fiscal year.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.